Joint statement offers new recommendations for treating cardiovascular conditions
the ONA take:
A new scientific statement issued jointly by the American Heart Association, American College of Cardiology, and American Society of Hypertension addresses treatment goals for patients with high blood pressure who also have vascular diseases.
The statement acknowledges that a target blood pressure of less than 140/90 mm Hg is reasonable to reduce the risk of heart attacks and strokes in the general population, a lower target of less than 130/80 mm Hg may be appropriate for some patients with heart disease who have already experienced a stroke, heart attack, or mini-stroke (transient ischemic attack [TIA]).
Additional recommendations and contraindications include which antihypertensives to use in patients with various types of heart disease. The statement also recommends lowering blood pressure slowly in patients with coronary artery blockages.
Furthermore, clinicians should not strive to lower the diastolic number to less than 60 mm Hg, especially in patients older than 60 years.
These recommendations also reiterate the importance of modifying other risk factors, including abdominal obesity, abnormal cholesterol, diabetes, and smoking.
New statement addresses treatment goals for patients with high blood pressure who also have vascular diseases.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|